Abbot
Albert G. Abbot, Clemson, SC US
Patent application number | Description | Published |
---|---|---|
20100170007 | GENES CONTROLLING WINTER DORMANCY IN PERENNIALS AND USES THEREOF - Provided herein are compositions and methods for modulating winter dormancy in a perennial plant using the herein disclosed winter dormancy genes and variants and homologues thereof. | 07-01-2010 |
Jamie Abbot, Mesa, AZ US
Patent application number | Description | Published |
---|---|---|
20120061001 | Vascular Graft with Kink Resistance After Clamping - A self-sealing vascular graft with kink resistance is described. The vascular graft includes a substrate that can be ePTFE, having a self-sealing region that may include several layers of material. The central section of the vascular graft may be constructed differently from surrounding self-sealing regions, in order to provide kink resistance following the clamping of the graft. Also described is a graft with a flared cuff attached to one or both ends, the attachment or transition region including reinforcement beading. | 03-15-2012 |
Jonathan Abbot, Saratoga Springs, UT US
Patent application number | Description | Published |
---|---|---|
20140127446 | AMORPHOUS CARBON AND ALUMINUM MEMBRANE - A membrane including at least one aluminum layer and at least one amorphous carbon layer. At least one polymer layer may also be included. Aluminum layer(s) can provide improved gas impermeability to the membrane. Amorphous carbon layer(s) can provide corrosion resistance. Polymer layer(s) can provide improved structural strength. | 05-08-2014 |
20140140487 | AMORPHOUS CARBON AND ALUMINUM X-RAY WINDOW - An x-ray window including at least one aluminum layer and at least one amorphous carbon layer. At least one polymer layer may also be included. Aluminum layer(s) can provide improved gas impermeability to the window. Amorphous carbon layer(s) can provide corrosion resistance. Polymer layer(s) can provide improved structural strength. | 05-22-2014 |
Kelly Abbot, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20100005520 | PERSONAL AREA SOCIAL NETWORKING - Techniques for managing the exchange of contact information are provided. Requests to establish connections on social networks and/or exchange contact information between users are held in escrow. The level of contact information and/or social network information shared between the users is configurable on a per user basis. Users may define levels of contact information and social network information to be shared with others based on the type of contact. Spam protection may be provided by requiring that both parties consent to a connection request before connections between the users are established. | 01-07-2010 |
Michael Lawrence Abbot, New London, CT US
Patent application number | Description | Published |
---|---|---|
20150328663 | METHODS AND SYSTEMS FOR MOISTURE REVEALED INDICIA ON GLASS AND OTHER SURFACES - A method for applying moisture revealed indicia to glass and other surfaces is provided. In some embodiments, the method may include: polishing a surface; changing the moisture condensing properties of portions of the surface by applying a surface tension modifier agent to those portions of the surface; and polishing the portions of the surface to which the surface tension modifier agent has been applied. Upon exposure of the surface to moisture, such as in the form of steam generated by the use of hot water in the vicinity of the surface or by steam generators, portions of the moisture revealed indicia may be formed by moisture revealed contrast | 11-19-2015 |
Philip Abbot, Leicestershire GB
Patent application number | Description | Published |
---|---|---|
20090082332 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS - The present invention provides compounds of formula (I) | 03-26-2009 |
Richard Abbot, Belle Mead, NJ US
Patent application number | Description | Published |
---|---|---|
20160007288 | OPPORTUNISTIC INFORMATION FORWARDING USING WIRELESS TERMINALS IN THE INTERNET-OF-THINGS - A capability for opportunistic forwarding of information using a wireless terminal is presented. An energy limited node includes a wake-up circuit configured to detect a wake-up signal from a wireless terminal where the wake-up signal includes a modulated waveform signal, and a communication module configured to switch, based on a control signal generated by the wake-up circuit, from a sleep mode in which the communication module is not operable to communicate with the wireless terminal to an active mode in which the communication module is operable to communicate with the wireless terminal. A wireless terminal includes a first wireless communication interface configured for communication with a device using a wireless communication protocol, a second wireless communication interface configured for wireless communication with a wireless access node of a wireless network, and a processor configured to support opportunistic forwarding of information between the device and the wireless access node of the wireless network. | 01-07-2016 |
Richard M. Abbot, Belle Mead, NJ US
Patent application number | Description | Published |
---|---|---|
20120081504 | AUDIO SOURCE LOCATOR AND TRACKER, A METHOD OF DIRECTING A CAMERA TO VIEW AN AUDIO SOURCE AND A VIDEO CONFERENCING TERMINAL - An audio locating and tracking apparatus, a method of directing a camera to view an audio source, and a video conferencing terminal are disclosed herein. In one embodiment, the apparatus includes: (1) an audio source identifier configured to locate an audio source based on multimodal sensor data from at least two different types of sensors and (2) an image selector configured to automatically direct a camera to view the audio source. | 04-05-2012 |
20120216129 | METHOD AND APPARATUS FOR PROVIDING AN IMMERSIVE MEETING EXPERIENCE FOR REMOTE MEETING PARTICIPANTS - An immersive meeting capability is depicted and described herein. The immersive meeting capability is configured for improving various aspects of a meeting held between one or more local participants located at a physical location at which the meeting is being held and one or more remote participants remote from the physical location at which the meeting is being held. The immersive meeting capability enables the remote participants to access and/or control one or more devices located at the physical location at which the meeting is being held and/or one or more views associated with the physical location at which the meeting is being held, thereby enabling remote participants to become immersed into the meeting. | 08-23-2012 |
Sarah C. Abbot, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20080287458 | Dihydroquinone and dihydronaphthridine inhibitors of JNK - Compounds of formula I are effective modulators of JNK: | 11-20-2008 |
Sarah C. Abbot, Erie, PA US
Patent application number | Description | Published |
---|---|---|
20100226879 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - Compounds having the formula A-R wherein A is a hetereoaryl and R is Ia, Ib or Ic and wherein A, R, R | 09-09-2010 |
Stephen Allen Abbot, Waikanae NZ
Patent application number | Description | Published |
---|---|---|
20090256686 | POWER LINE COMMUNICATION SYSTEM AND AN INTELLIGENT METER - A power line communication system including a plurality of intelligent devices in communication with a power line and operable to monitor energy usage at a site and communicate usage data onto the power line, and a controller also in communication with the power line, wherein each intelligent device maintains a routing table identifying a first set of other intelligent devices downstream of it relative to the controller that it can communicate with directly and identifying a second set of other intelligent devices downstream of it relative to the controller that it can communicate with through one or more of the first set of other intelligent devices. | 10-15-2009 |
20120188063 | POWER LINE COMMUNICATION SYSTEM AND AN INTELLIGENT METER - A power line communication system including a plurality of intelligent devices in communication with a power line and operable to monitor energy usage at a site and communicate usage data onto the power line, and a controller also in communication with the power line, wherein each intelligent device maintains a routing table identifying a first set of other intelligent devices downstream of it relative to the controller that it can communicate with directly and identifying a second set of other intelligent devices downstream of it relative to the controller that it can communicate with through one or more of the first set of other intelligent devices. | 07-26-2012 |
20130136132 | POWER LINE COMMUNICATION SYSTEM AND AN INTELLIGENT METER - A power line communication system including a plurality of intelligent devices in communication with a power line and operable to monitor energy usage at a site and communicate usage data onto the power line, and a controller also in communication with the power line, wherein each intelligent device maintains a routing table identifying a first set of other intelligent devices downstream of it relative to the controller that it can communicate with directly and identifying a second set of other intelligent devices downstream of it relative to the controller that it can communicate with through one or more of the first set of other intelligent devices. | 05-30-2013 |
Stephen N. Abbot, Austin, TX US
Patent application number | Description | Published |
---|---|---|
20110271136 | PREDICTIVELY MANAGING FAILOVER IN HIGH AVAILABILITY SYSTEMS - A method, system, and computer usable program product for predictively managing failover in a high availability system are provided in the illustrative embodiments. A disruptive activity occurring on the HA data processing system is detected. The disruptive activity has a potential to cause an operation of the HA data processing system to perform outside a specified parameter. A determination is made of a desired response in the HA data processing system should the disruptive activity disrupting the operation. A precautionary action is initiated with respect to the HA data processing system. | 11-03-2011 |
Stewart Abbot, Warren, NJ US
Patent application number | Description | Published |
---|---|---|
20100124569 | AMNION DERIVED ADHERENT CELLS - Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals. | 05-20-2010 |
20110003387 | METHOD OF PRODUCING ERYTHROCYTES WITHOUT FEEDER CELLS - Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place. | 01-06-2011 |
20110250182 | ANGIOGENESIS USING PLACENTAL STEM CELLS - Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells. | 10-13-2011 |
20120156230 | TREATMENT OF SPINAL CORD INJURY AND TRAUMATIC BRAIN INJURY USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an injury to the central nervous system, such as a spinal cord injury or a traumatic brain injury, using placental stem cells and placental multipotent stem cells described herein, and populations of such placental cells. | 06-21-2012 |
20120164114 | TREATMENT OF IMMUNE-RELATED DISEASES AND DISORDERS USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of using amnion derived adherent cells, and populations of, and compositions comprising, such cells, in the modulation of an immune response. In various embodiments, the immune response is graft-versus-host disease, an allergy, asthma, or an immune-related disease or disorder, e.g., an autoimmune disease. | 06-28-2012 |
20120201787 | TREATMENT OF SPINAL CORD INJURY AND TRAUMATIC BRAIN INJURY USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of treating spinal cord and traumatic brain injuries using cells from amnion, and populations of such cells, referred to herein as “amnion derived adherent cells” (“AMDACs”). | 08-09-2012 |
20120230959 | ENHANCEMENT OF PLACENTAL STEM CELL POTENCY USING MODULATORY RNA MOLECULES - Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells. | 09-13-2012 |
20130315875 | AMNION DERIVED ADHERENT CELLS - Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals. | 11-28-2013 |
20140256042 | METHOD OF PRODUCING ERYTHROCYTES WITHOUT FEEDER CELLS - Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place. | 09-11-2014 |
20150118265 | MODIFIED ERYTHROCYTE PRECURSOR CELLS AND USES THEREOF - Provided herein are modified erythrocyte precursor cells, erythrocytes generated from modified erythrocyte precursor cells, and uses thereof. | 04-30-2015 |
20150190434 | ENHANCEMENT OF PLACENTAL STEM CELL POTENCY USING MODULATORY RNA MOLECULES - Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells. | 07-09-2015 |
20150225697 | NATURAL KILLER CELLS AND USES THEREOF - Provided herein are methods of producing natural killer (NK) cells and NK progenitor cell populations using a two-step expansion and differentiation method. Also provided herein are methods of producing populations of NK cells and NK progenitor cell populations using a three-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells, the NK cell populations, and the NK progenitor cell populations produced by the methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells, the NK cell populations, and the NK progenitor cell populations produced by the methods described herein to an individual having the cancer or viral infection. | 08-13-2015 |
20150307623 | CHIMERIC ANTIGEN RECEPTORS - Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer. | 10-29-2015 |
20150307879 | ANOIKIS RESISTANT PLACENTAL STEM CELLS AND USES THEREOF - Anoikis resistant placental stem cells (arPSCs) with increased survival in low-attachment environments, and thus can advantageously be used, e.g., in therapies based on their ability to persist for longer durations of time in an unattached state. A method of modifying placental stem cells to make them anoikis resistant, comprising contacting the placental stem cells with an effective amount of modulatory RNA molecules, such that one or more genes associated with anoikis of the placental stem cells is inhibited. Further discloses are genes that are associated with anoikis for modulation. | 10-29-2015 |
20150366910 | NATURAL KILLER CELLS FROM PLACENTA - Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood. | 12-24-2015 |
20150368360 | MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY - Provided herein are modified T lymphocytes comprising chimeric receptors and methods of use thereof. | 12-24-2015 |
Stewart Abbot US
Patent application number | Description | Published |
---|---|---|
20150225697 | NATURAL KILLER CELLS AND USES THEREOF - Provided herein are methods of producing natural killer (NK) cells and NK progenitor cell populations using a two-step expansion and differentiation method. Also provided herein are methods of producing populations of NK cells and NK progenitor cell populations using a three-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells, the NK cell populations, and the NK progenitor cell populations produced by the methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells, the NK cell populations, and the NK progenitor cell populations produced by the methods described herein to an individual having the cancer or viral infection. | 08-13-2015 |
Stewart E. Abbot, Niskayuna, NY US
Patent application number | Description | Published |
---|---|---|
20080304732 | AUTOMATIC CHARACTERIZATION OF CELLULAR MOTION - The present techniques provide for the evaluation of cellular motion and/or cellular properties based on an analysis of motion. In an exemplary technique, images of one or more cells are acquired and motion data for the one or more cells is derived from the images. The motion data is decomposed to generate one or more motion components. The one or more motion components can be used to evaluate cellular properties and/or cellular motion properties. | 12-11-2008 |